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Materials and methods 
NMR: Bruker AVANCE-400 (400 MHz), ASCEND-500 (500 MHz) or Bruker 
AVANCE II+ 600 MHz. 
ESI-TOF MS: Bruker micrOTOF II.  
Fluorescence microscopy: Optika N400-FL microscope equipped with 40X objective 
and CCD camera. 
Solvents and reagents: TCI Co., Ltd., Wako Pure Chemical Industries Ltd., Kanto 
Chemical Co., Inc., Sigma-Aldrich Co., and Cambridge Isotope Laboratories, Inc.  
Compounds: Ligand 2 and capsules 1Pt and 1Pd were synthesized following procedures 
described previously.[1,2] 
 
Synthesis of 1Pt•(Pyr)2 and 1Pd•(Pyr)2 composites 
A 1:2 host-guest composite, 1Pt•(Pyr)2, was synthesized from Pt(II) capsule 1Pt and 
pyrene (Pyr) according to the previously reported procedure.[3] A 1Pd•(Pyr)2 composite 
was also prepared by the similar procedure. 
Physical data of 1Pt•(Pyr)2: 1H NMR (500 MHz, D2O:CD3OD = 1:2, r.t.): δ 3.14 (m, 
28H, 1Pt and Pyr), 3.62-3.78 (m, 24H, 1Pt and Pyr), 3.99 (s, 12H, 1Pt), 4.03 (d, J = 9.0 
Hz, 4H, Pyr), 4.45 (m, 8H, 1Pt), 4.56-4.73 (m, 20H, 1Pt and Pyr), 5.06 (m, 8H, 1Pt), 5.60 
(s, 8H, 1Pt), 6.75 (d, J = 8.5 Hz, 8H, 1Pt), 6.97 (s, 4H, 1Pt), 7.23 (d, J = 8.5 Hz, 8H, 1Pt), 
7.71 (dd, J = 8.5, 7.5 Hz, 8H, 1Pt), 7.89 (dd, J = 8.5, 7.5 Hz, 8H, 1Pt), 8.27-8.35 (m, 16H, 
1Pt), 8.44 (dd, J = 8.0, 5.5 Hz, 8H, 1Pt), 8.50 (d, J = 8.5 Hz, 8H, 1Pt), 8.63 (d, J = 8.5 Hz, 
8H, 1Pt), 8.73 (d, J = 5.5 Hz, 8H, 1Pt), 8.87 (d, J = 8.0 Hz, 8H, 1Pt). ESI-TOF MS 
(H2O:CH3OH): m/z 2072.3 [1Pt•(Pyr)2 – 2•NO3–]2+, 1360.9 [1Pt•(Pyr)2 – 3•NO3–]3+, 
1005.2 [1Pt•(Pyr)2 – 4•NO3–]4+.  
Physical data of 1Pd•(Pyr)2: 1H NMR (500 MHz, D2O:CD3OD = 1:2, r.t.): δ 3.13 (s, 24H, 
1Pd), 3.18 (d, J = 7.5 Hz, 4H, Pyr), 3.60-3.81 (m, 24H, 1Pd and Pyr), 3.99 (s, 12H, 1Pd), 
4.06 (d, J = 8.5 Hz, 4H, Pyr), 4.49 (m, 8H, 1Pd), 4.58-4.71 (m, 20H, 1Pd and Pyr), 5.05 
(m, 8H, 1Pd), 5.55 (s, 8H, 1Pd), 6.69 (d, J = 8.5 Hz, 8H, 1Pd), 6.99 (s, 4H, 1Pd), 7.22 (d, J 
= 8.5 Hz, 8H, 1Pd), 7.68 (dd, J = 8.5, 7.5 Hz, 8H, 1Pd), 7.88 (dd, J = 8.5, 7.5 Hz, 8H, 
1Pd), 8.25-8.34 (m, 16H, 1Pd), 8.43 (dd, J = 8.0, 5.5 Hz, 8H, 1Pd), 8.50 (d, J = 8.5 Hz, 
8H, 1Pd), 8.62 (d, J = 8.5 Hz, 8H, 1Pd), 8.67 (d, J = 5.5 Hz, 8H, 1Pd), 8.83 (d, J = 8.0 Hz, 
8H, 1Pd). ESI-TOF MS (H2O:CH3OH = 1:2): m/z 1983.8 [1Pd•(Pyr)2 – 2•NO3–]2+, 
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Figure S2b. ESI-TOF MS spectrum (H2O:CH3OH = 1:2) of 1Pd•(Pyr)2. 
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Stability of capsules 1Pt and 1Pd toward biomolecules  
Stability of capsules 1Pt and 1Pd in presence of various biomolecules (shown in Figure 
2) was studied by mixing the substances in D2O:CD3OD (3:2) solutions in molar ratios 
of capsule:biomolecule from 1:2 to 1:100. The resultant solutions were stirred at 50 ºC 
(or room temperature) and monitored by 1H NMR spectroscopy in the course of 1 to 3 
days. The interaction of the capsules with glutathione was additionally studied in a 
DMSO-d6:D2O (10:1) solution in order to avoid an eventual precipitation. 
 
 
Figure S3. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pt, b) 1Pt + phenylalanine 
(1 equiv.), c) 1Pt + phenylalanine (2 equiv.), d) 1Pt + phenylalanine (4 equiv.), and e) 1Pt + 




Figure S4. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pt, b) 1Pt + tryptophan (1 
equiv.), c) 1Pt + tryptophan (4 equiv.), d) 1Pt + tryptophan (6 equiv.), and e) tryptophan (in D2O). 
 






Figure S5a. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pt, b) 1Pt + valine (1 
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Figure S5b. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pd, b) 1Pd + valine (1 
equiv.), c) 1Pd + valine (10 equiv.), and d) 1Pd + valine (100 equiv.). 
 
 
Figure S6a. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pt, b) 1Pt + proline (1 
equiv.), c) 1Pt + proline (2 equiv.), d) 1Pt + proline (4 equiv.), e) 1Pt + proline (6 equiv.), and f) 




Figure S7a. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pt, b) 1Pt + cysteine (1 
equiv.), c) 1Pt + cysteine (2 equiv.), d) 1Pt + cysteine (4 equiv.), e) 1Pt + cysteine (6 equiv.), and 
f) cysteine (in D2O). 
 




Figure S7b. 1H NMR spectra (500 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pt + cysteine (~100 
equiv.) and b) 1Pd + cysteine (~100 equiv.). 
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Figure S8a. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pt, b) 1Pt + adenine (1 
equiv.), c) 1Pt + adenine (10 equiv.), and d) 1Pt + adenine (100 equiv.). 
 






Figure S8b. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1Pd, b) 1Pd + adenine (1 




Figure S9. 1H NMR spectra (400 MHz, D2O:CD3OD = 3:2, r.t.) of a) 1’Pd, b) 1’Pd + adenine, c) 




Figure S10. 1H NMR spectra (600 MHz, DMSO-d6:D2O = 10:1, r.t.) of 1Pt + glutathione (10 
equiv.) measured immediately after mixing (a) and after b) 1h 30 min, c) 4h 30 min, d) 7h 30 
min, and e) 3 days in air. 
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Cancer cell growth inhibitory evaluation 
Cell lines and culture conditions: The pharmacological study was carried out using 
human tumor cell lines, namely HL-60 (acute myelocyte leukemia), its 
cisplatin-resistant sub-line HL-60/CDDP, and SKW-3 (T-cell leukemia), as well as a 
human embryonic kidney cell line HEK-293, utilized as an in vitro model for 
nephrotoxicity. The cisplatin-resistant sub-line HL-60/CDDP has been developed at the 
Lab of Experimental Chemotherapy (Faculty of Pharmacy, MU-Sofia). It was 
established by continuous selection in medium with gradually increasing concentrations 
of cisplatin. HL-60 were obtained from the German Collection of Microorganisms and 
Cell Cultures (DSMZ GmbH, Braunschweig, Germany). The cells were cultured in a 
controlled environment – cell culture flasks at 37 °C in an incubator ‘BB 16-Function 
Line’ Heraeus (Kendro, Hanau, Germany) with humidified atmosphere and 5% CO2. 
The growth medium was 90% RPMI-1640 + 10% FBS. HL-60/CDDP cells were grown 
in the presence of 25 µmol/L cisplatin in order to maintain their drug resistance 
phenotype. 
 
MTT-dye reduction assay: The tumor cell growth inhibitory effects of the tested 
compounds were evaluated using the MTT-dye reduction assay, as previously 
described,[4] with slight modifications.[5] In brief, exponentially proliferating cells were 
seeded in 96-well flat-bottomed microplates (100 µL/well; at a density of 1 × 105 
cells/mL for the leukemic cells) and incubated for 24 h at 37 °C, in an incubator. 
Thereafter the cells were exposed to serial dilutions of the tested compounds for 72 h. 
For each treatment-group a set of at least 8 wells was used. After the exposure period 10 
µL aliquots of MTT solution (10 mg/mL in PBS) were pipetted in each well. Thereafter 
the microplates were incubated for further 4 h at 37 °C and the MTT-formazan crystals 
formed were dissolved through addition of 100 µL/well 5% formic acid solution in 
2-propanol. The MTT-formazan absorption was determined using a multimode 
microplate reader (Beckman Coulter DTX-880) at 580 nm. The bioassay data were 
normalized as percentage of the untreated control (set as 100% viable) and fitted to 
sigmoidal dose response curves allowing the determination of the equieffective IC50 
concentrations (concentrations inducing 50% suppression of cellular viability). In 
addition, the resistance indices as a relative merit for the level of resistance in 
HL-60/CDDP were determined as the ratio between the IC50 in the multi-drug resistant 
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HL-60/CDDP and the corresponding IC50 in the sensitive parent line HL-60. All tests 
were run in triplicate. 
 
In vitro nephrotoxicity and selectivity study  
In order to identify the anticancer selectivity of 1Pt, 1Pd and cisplatin the inhibitory 
effects of these agent in HEK-293, where compared to those in the cancer cell lines. To 
meet this objective the selectivity indices were calculated as a ratio between the IC50 
obtained in HEK-293 and the arithmetic mean of the IC50 values established in the 
malignant cell lines (in case of cisplatin the value in HL-60/CDDP was ignored as this 
cell line is not-responsive to this drug). 
 
Table S1. Estimated IC50 values of capsules 1Pt and 1Pd, cisplatin, and ligand 2 against 







1Pt 6.6 ± 0.9 
1.7 ± 0.3 
(0.26) 
2.3 ± 0.8 26.4 ± 3.1 
1Pd 1.9 ± 0.2 
1.0 ± 0.04 
(0.51) 
1.8 ± 0.2 18.3 ± 1.2 
cisplatin 8.1 ± 1.4 
124.4 ± 11.7 
(15.4) 
9.3 ± 2.1 19.3 ± 2.2 
ligand 2 > 100 n.d. > 80 n.d. 
[a]Resistance index (RI) = IC50(HL-60/CDDP)/IC50(HL-60).
 n.d. - Not determined 
 
Fluorescence microscopy imaging study  
We made fluorescence microscopy imaging of the HL-60 cells after treating them with 
ligand 2 and capsules 1M (M = Pd and Pt) (10 µM each) for 4 h (Figure S11). The cells 
were washed before fixing and imaging. The supernatant of the cells was used to 
measure the LDH-activity in a kinetic mode and using LDH Assay kit. As LDH (lactate 
dehydrogenase) is an enzyme that has higher concentration inside the cell, an eventually 
increased activity of this enzyme in the supernatant would suggest damage of the cells 
membrane. Our results showed that in all four cases (3 compounds + control) the LDH 
activity is comparable (ranging from 84-120 U/L with the highest activity in the control). 
These results suggested that the compounds do not destroy the cell membranes for at 
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least 4 h. In the Figure 11c, the observed, strong blue fluorescence inside the cells are 
derived from the decomposition of the non-fluorescent Pd(II) capsule, because the free 
ligand provides strong fluorescent properties (Figure 11b). At the same time the 
supernatant of the cells treated with the capsules exhibit negligible (for Pd capsule) or 
no fluorescence emission (for Pt capsule) in contrast to the supernatant of cells treated 
with the free ligand 2. 
 
 
Figure S11. Fluorescence microscopy images (left: transmitted light and right: fluorescent light) 
of a) HL-60 cells (control) and HL-60 cells treated with: b) ligand 2, c) 1Pd capsule, and d) 1Pt 
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